Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ousia Pharma
Copenhagen, Denmark
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Ousia Pharma is developing once-weekly peptide-drug conjugates for obesity, leveraging hormone analogues to deliver NMDA receptor antagonists to the brain's appetite control centers. In mouse models, these conjugates have demonstrated significant efficacy and may allow lower doses to reduce side effects, but are not yet clinically tested in humans.[1][2][3][4]
- Therapeutic areas
- NeurologyEndocrinologyMetabolic Disorders
- Modalities
- Peptide-drug conjugateSynthetic peptideSmall molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Ousia Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ousia Pharma.